Skip to main content
Equibles
CALC logo

CALC · CalciMedica, Inc. · Metrics

Track CALC — free

Use CALC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CALC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.07 +0.05 (+4.41%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's current operating plans, management believes its cash and cash equivalents may not be sufficient to fund its operations for a period of one year following the issuance of these financial statements. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$7.27M
Shares
6.83M
Volume · Oct 20 41.81K Avg daily vol (35 sessions) 75.7K

CALC metrics

54 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.02
Market cap
$7.27M

Price action

20 metrics
Price change (1W)
-15.4%
Price change (30D)
-45.2%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
17.5
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
75,701
Relative volume
0.2
Average dollar volume
$135,775

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
6.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.3
reciprocal yield 79.9%
FCF yield
-277.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-307.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-07

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$19.63M
Net income (TTM)
−$21.24M
Trailing 12 months
Diluted EPS (TTM)
$-6.80
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-6.14
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-6.70
Operating cash flow per diluted share (TTM)
$-5.95
Free cash flow per diluted share (TTM)
$-5.96
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$3.94
Stock compensation per diluted share (TTM)
$0.73
Book value per share
$-2.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-385.3%
Return on assets
-108.9%
Debt / equity
—
Current ratio
5.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$19.12M
Quick ratio
5.6
Interest coverage
-15.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$18.62M
Latest balance sheet
Cash & equivalents
$18.62M
Total assets
$19.50M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.11M
Capital expenditures (TTM)
$14,000
R&D (TTM)
$12.54M
SG&A (TTM)
—
Stock compensation (TTM)
$2.35M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
32
13F filer change QoQ
+4
Institutional ownership
24.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
47.4%
Private-fund adviser ownership
36.3%
Active holders' share change QoQ
+982.9%
Holder tenure
1.3
Price vs estimated holder cost
+25.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.6%

Short interest

3 metrics
Short interest
1.3%
Latest settlement · 1.5 days to cover
Days to cover
1.5d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1534133 CUSIP 38942Q301 13F (30d) 1 filings 1 filers Visit website Investor relations